Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

REAL-WORD EXPERIENCE WITH DECITABINE AS A FIRST-LINE TREATMENT IN 306 ELDERLY ACUTE MYELOID LEUKAEMIA PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY.

Bocchia M, Candoni A, Borlenghi E, Defina M, Filì C, Cattaneo C, Sammartano V, Fanin R, Sciumè M, Sicuranza A, Imbergamo S, Riva M, Fracchiolla N, Latagliata R, Caizzi E, Mazziotta F, Alunni G, Di Bona E, Crugnola M, Rossi M, Consoli U, Fontanelli G, Greco G, Nadali G, Rotondo F, Todisco E, Bigazzi C, Capochiani E, Molteni A, Bernardi M, Fumagalli M, Rondoni M, Scappini B, Ermacora A, Simonetti F, Gottardi M, Lambertenghi Deliliers D, Michieli MG, Basilico C, Galeone C, Pelucchi C, Rossi G.

Hematol Oncol. 2019 Aug 5. doi: 10.1002/hon.2663. [Epub ahead of print]

PMID:
31385337
2.

The Italian Mastocytosis Registry: 6-year experience from a hospital-based registry.

Merante S, Ferretti VV, Elena C, Brazzelli V, Zanotti R, Neri I, Magliacane D, Belloni Fortina A, Ingeborg F, Pastorello EA, Pieri L, Papayannidis C, Mauro M, Grifoni F, Minelli R, Guggiari E, Difonzo E, Bocchia M, Caroppo F, Di Nuzzo S, Elli EM, Rondoni M, Ciccocioppo R, Di Stefano M, Bossi G, Boveri E, Bonadonna P, Giona F, Valent P, Triggiani M.

Future Oncol. 2018 Nov;14(26):2713-2723. doi: 10.2217/fon-2018-0291. Epub 2018 Sep 12.

PMID:
30207489
3.

SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis.

Martinelli G, Mancini M, De Benedittis C, Rondoni M, Papayannidis C, Manfrini M, Meggendorfer M, Calogero R, Guadagnuolo V, Fontana MC, Bavaro L, Padella A, Zago E, Pagano L, Zanotti R, Scaffidi L, Specchia G, Albano F, Merante S, Elena C, Savini P, Gangemi D, Tosi P, Ciceri F, Poletti G, Riccioni L, Morigi F, Delledonne M, Haferlach T, Cavo M, Valent P, Soverini S.

Leukemia. 2018 Jan;32(1):139-148. doi: 10.1038/leu.2017.183. Epub 2017 Jun 16.

4.

Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients.

Pieri L, Bonadonna P, Elena C, Papayannidis C, Grifoni FI, Rondoni M, Girlanda S, Mauro M, Magliacane D, Elli EM, Iorno ML, Almerigogna F, Scarfì F, Salerno R, Fanelli T, Gesullo F, Corbizi Fattori G, Bonifacio M, Perbellini O, Artuso A, Soverini S, De Benedittis C, Muratori S, Pravettoni V, Cova V, Cortellini G, Ciceri F, Cortelezzi A, Martinelli G, Triggiani M, Merante S, Vannucchi AM, Zanotti R.

Am J Hematol. 2016 Jul;91(7):692-9. doi: 10.1002/ajh.24382. Epub 2016 Jun 2.

5.

Serendipitous detection of Hemoglobin G-Ferrara variant with Sysmex DIFF channel.

Rosetti M, Poletti G, Ivaldi G, Rondoni M, Baldrati L, Dorizzi RM.

Clin Biochem. 2016 Jan;49(1-2):192-3. doi: 10.1016/j.clinbiochem.2015.09.009. Epub 2015 Sep 21. No abstract available.

PMID:
26391219
6.

A rare case of Hemoglobin Leiden interfering with the DIFF channel of Sysmex XE-2100.

Rosetti M, Poletti G, Sensi A, Ravani A, Rondoni M, Baldrati L, Dorizzi RM.

Scand J Clin Lab Invest. 2015 Sep;75(5):436-7. doi: 10.3109/00365513.2015.1033743. Epub 2015 Apr 15. No abstract available.

PMID:
25874481
7.

Serum total tryptase level confirms itself as a more reliable marker of mast cells burden in mast cell leukaemia (aleukaemic variant).

Savini P, Rondoni M, Poletti G, Lanzi A, Quercia O, Soverini S, De Benedittis C, Musardo G, Martinelli G, Stefanini GF.

Case Rep Hematol. 2015;2015:737302. doi: 10.1155/2015/737302. Epub 2015 Feb 10.

8.

Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias.

Fianchi L, Pagano L, Piciocchi A, Candoni A, Gaidano G, Breccia M, Criscuolo M, Specchia G, Maria Pogliani E, Maurillo L, Aloe-Spiriti MA, Mecucci C, Niscola P, Rossetti E, Mansueto G, Rondoni M, Fozza C, Invernizzi R, Spadea A, Fenu S, Buda G, Gobbi M, Fabiani E, Sica S, Hohaus S, Leone G, Voso MT.

Am J Hematol. 2015 May;90(5):E80-5. doi: 10.1002/ajh.23966. Epub 2015 Mar 3.

9.

Extraperitoneal radical cystectomy and ureterocutaneostomy in octogenarians.

De Nunzio C, Cicione A, Leonardo F, Rondoni M, Franco G, Cantiani A, Tubaro A, Leonardo C.

Int Urol Nephrol. 2011 Sep;43(3):663-7. doi: 10.1007/s11255-010-9876-7. Epub 2010 Nov 26.

PMID:
21110093
10.

Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination.

Bocchia M, Defina M, Aprile L, Ippoliti M, Crupi R, Rondoni M, Gozzetti A, Lauria F.

Nat Rev Clin Oncol. 2010 Oct;7(10):600-3. doi: 10.1038/nrclinonc.2010.141. Epub 2010 Aug 31.

PMID:
20808301
11.

A der(1)t(1;21)(p36.3;q22) in a patient with acute myelogenous leukemia M2.

Gozzetti A, Crupi R, Rondoni M, Defina M, Bocchia M, Pietrini A, Raspadori D, Lauria F.

Acta Haematol. 2010;124(1):44-5. doi: 10.1159/000314075. Epub 2010 Jul 3. No abstract available.

PMID:
20606416
12.

Very late relapse in a patient with chronic myeloid leukemia in sustained complete cytogenetic response under imatinib.

Defina M, Gozzetti A, Rondoni M, Aprile L, Ippoliti M, Chitarrelli I, Lauria F, Bocchia M.

Leuk Res. 2010 Aug;34(8):e215-6. doi: 10.1016/j.leukres.2010.02.037. Epub 2010 Mar 23. No abstract available.

PMID:
20334915
13.

Translocation(X;2)(q26;q11.2) in a patient with acute myeloid leukemia M2 evolved from essential thrombocytemia.

Gozzetti A, Crupi R, Rondoni M, Daviddi B, Defina M, Bocchia M, Pietrini A, Raspadori D, Lauria F.

Cancer Genet Cytogenet. 2010 Feb;197(1):84-5. doi: 10.1016/j.cancergencyto.2009.05.006. No abstract available.

PMID:
20113843
14.

Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion.

Defina M, Rondoni M, Gozzetti A, Aprile L, Chitarrelli I, Fabbri A, Lauria F, Bocchia M.

Br J Haematol. 2010 Feb;148(3):483-4. doi: 10.1111/j.1365-2141.2009.07971.x. Epub 2009 Oct 28. No abstract available.

PMID:
19874309
15.

Advanced mast cell disease: an Italian Hematological Multicenter experience.

Pagano L, Valentini CG, Caira M, Rondoni M, Van Lint MT, Candoni A, Allione B, Cattaneo C, Marbello L, Caramatti C, Pogliani EM, Iannitto E, Giona F, Ferrara F, Invernizzi R, Fanci R, Lunghi M, Fianchi L, Sanpaolo G, Stefani PM, Pulsoni A, Martinelli G, Leone G, Musto P.

Int J Hematol. 2008 Dec;88(5):483-488. doi: 10.1007/s12185-008-0166-4. Epub 2008 Nov 26.

PMID:
19034614
16.

Long-term molecular complete remission with IFN-alpha in Ph+ adult acute lymphoid leukemia patients.

Piccaluga PP, Martinelli G, Isidori A, Malagola M, Rondoni M, Paolini S, Amabile M, Iacobucci I, Baccarani M, Visani G.

Leukemia. 2008 Aug;22(8):1617-8. doi: 10.1038/leu.2008.10. Epub 2008 Feb 14. No abstract available.

PMID:
18273047
17.

Mast cell leukemia: a report of ten cases.

Valentini CG, Rondoni M, Pogliani EM, Van Lint MT, Cattaneo C, Marbello L, Pulsoni A, Giona F, Martinelli G, Leone G, Pagano L.

Ann Hematol. 2008 Jun;87(6):505-8. doi: 10.1007/s00277-007-0430-3. Epub 2008 Jan 3. No abstract available.

PMID:
18172645
18.

Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study.

Piccaluga PP, Malagola M, Rondoni M, Arpinati M, Paolini S, Candoni A, Fanin R, Messa E, Pirrotta MT, Lauria F, Visani G, Alberti D, Rancati F, Vinaccia V, Russo D, Saglio G, Baccarani M, Martinelli G.

Haematologica. 2007 Dec;92(12):1721-2.

19.

Imatinib mesylate in the treatment of hematologic malignancies.

Piccaluga PP, Rondoni M, Paolini S, Rosti G, Martinelli G, Baccarani M.

Expert Opin Biol Ther. 2007 Oct;7(10):1597-611. Review.

PMID:
17916051
20.

The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study.

Baccarani M, Cilloni D, Rondoni M, Ottaviani E, Messa F, Merante S, Tiribelli M, Buccisano F, Testoni N, Gottardi E, de Vivo A, Giugliano E, Iacobucci I, Paolini S, Soverini S, Rosti G, Rancati F, Astolfi C, Pane F, Saglio G, Martinelli G.

Haematologica. 2007 Sep;92(9):1173-9. Epub 2007 Aug 1.

21.

PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment.

Vigna E, Lucia E, Gentile M, Mazzone C, Bisconte MG, Gentile C, Armentano A, Ottaviani E, Rondoni M, Martinelli G, Morabito F.

Cancer Chemother Pharmacol. 2008 Apr;61(4):713-6. Epub 2007 Jun 5.

PMID:
17549478
22.

WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia.

Cilloni D, Messa F, Martinelli G, Gottardi E, Arruga F, Defilippi I, Carturan S, Messa E, Fava M, Giugliano E, Rosso V, Catalano R, Merante S, Nicoli P, Rondoni M, Ottaviani E, Soverini S, Tiribelli M, Pane F, Baccarani M, Saglio G.

Leukemia. 2007 Jul;21(7):1442-50. Epub 2007 May 17.

PMID:
17508006
23.

Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.

Soverini S, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C, Paolini S, Rondoni M, Piccaluga PP, Palandri F, Giannoulia P, Marzocchi G, Luatti S, Testoni N, Iacobucci I, Cilloni D, Saglio G, Baccarani M, Martinelli G.

Haematologica. 2007 Mar;92(3):401-4.

24.

Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL.

Soverini S, Martinelli G, Colarossi S, Gnani A, Rondoni M, Castagnetti F, Paolini S, Rosti G, Baccarani M.

Lancet Oncol. 2007 Mar;8(3):273-4. No abstract available.

PMID:
17329198
25.

Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.

Jovanovic JV, Score J, Waghorn K, Cilloni D, Gottardi E, Metzgeroth G, Erben P, Popp H, Walz C, Hochhaus A, Roche-Lestienne C, Preudhomme C, Solomon E, Apperley J, Rondoni M, Ottaviani E, Martinelli G, Brito-Babapulle F, Saglio G, Hehlmann R, Cross NC, Reiter A, Grimwade D.

Blood. 2007 Jun 1;109(11):4635-40. Epub 2007 Feb 13.

26.

Nephro-ileal conduit subcutaneous stent: an alternative to percutaneous nephrostomy.

Leonardo C, Rondoni M, Meneschincheri F, Peris F, Leonardo F, De Nunzio C.

Minerva Urol Nefrol. 2006 Sep;58(3):165-7.

PMID:
17124487
27.

Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.

Soverini S, Martinelli G, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C, Paolini S, Rondoni M, Piccaluga PP, Palandri F, Giannoulia P, Marzocchi G, Luatti S, Testoni N, Iacobucci I, Cilloni D, Saglio G, Baccarani M.

J Clin Oncol. 2006 Nov 20;24(33):e51-2. No abstract available.

PMID:
17114651
28.

Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia.

Piccaluga PP, Martinelli G, Rondoni M, Visani G, Baccarani M.

Expert Opin Biol Ther. 2006 Oct;6(10):1011-22. Review.

PMID:
16989583
29.

C-erb-2 gene amplification and chromosomal anomalies in bladder cancer: preliminary results.

Leonardo C, Merola R, Orlandi G, Leonardo F, Rondoni M, De Nunzio C.

J Exp Clin Cancer Res. 2005 Dec;24(4):633-8.

PMID:
16471327
30.

Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation.

Piccaluga PP, Malagola M, Rondoni M, Ottaviani E, Testoni N, Laterza C, Visani G, Pileri SA, Martinelli G, Baccarani M.

Leuk Lymphoma. 2006 Mar;47(3):469-72.

PMID:
16396770
31.

Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.

Russo D, Malagola M, de Vivo A, Fiacchini M, Martinelli G, Piccaluga PP, Damiani D, Candoni A, Michielutti A, Castelli M, Testoni N, Ottaviani E, Rondoni M, Pricolo G, Mazza P, Zuffa E, Zaccaria A, Raspadori D, Bocchia M, Lauria F, Bonini A, Avanzini P, Gugliotta L, Visani G, Fanin R, Baccarani M.

Br J Haematol. 2005 Oct;131(2):172-9. Erratum in: Br J Haematol. 2006 Mar;132(6):804.

PMID:
16197446
32.

Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target?

Malagola M, Martinelli G, Rondoni M, Paolini S, Gaitani S, Arpinati M, Piccaluga PP, Amabile M, Basi C, Ottaviani E, Candoni A, Gottardi E, Cilloni D, Bocchia M, Saglio G, Lauria F, Fanin R, Visani G, Marrè MC, Maderna M, Rancati F, Vinaccia V, Russo D, Baccarani M.

Blood. 2005 Jan 15;105(2):904; author reply 905. No abstract available.

33.

Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia.

Piccaluga PP, Martinelli G, Malagola M, Rondoni M, Bonifazi F, Bandini G, Visani G, Baccarani M.

Leukemia. 2005 Jan;19(1):135; author reply 136. No abstract available.

PMID:
15510200
34.

The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients.

Piccaluga PP, Malagola M, Amabile M, Rondoni M, Paolini S, Pane F, Russo D, Visani G, Baccarani M, Martinelli G.

Haematologica. 2004 Oct;89(10):1269-71.

35.

Gross hematuria 10 years after radical cystectomy: adenomatous polyp.

Leonardo C, De Nunzio C, Rondoni M, Leonardo F.

Minerva Urol Nefrol. 2004 Sep;56(3):325-6.

PMID:
15467510
36.

Soft tissue and skeletal involvement in FIP1L1-PDGFR-alpha positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission.

Malagola M, Martinelli G, Rondoni M, Ottaviani E, Piccaluga PP, Ricci P, Visani G, Baccarani M.

Haematologica. 2004 Aug;89(8):ECR25. No abstract available.

37.

First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients.

Piccaluga PP, Martinelli G, Rondoni M, Malagola M, Gaitani S, Visani G, Baccarani M.

Leuk Res. 2004 Sep;28(9):987-90.

PMID:
15234577
38.

Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas.

Piccaluga PP, Martinelli G, Rondoni M, Malagola M, Gaitani S, Isidori A, Bonini A, Gugliotta L, Luppi M, Morselli M, Sparaventi G, Visani G, Baccarani M.

Leuk Lymphoma. 2004 Sep;45(9):1791-5.

PMID:
15223637
39.

Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation.

Piccaluga PP, Martinelli G, Malagola M, Rondoni M, Bianchini M, Vigna E, Bosi C, Gaitani S, Visani G, Baccarani M.

Leuk Lymphoma. 2004 Apr;45(4):731-3.

PMID:
15160947
40.

Prompt resolution of nasal aspergillosis with intranasal instillation of liposomal amphotericin-B (amBisome) and granulocyte transfusions.

Piccaluga PP, Ricci P, Martinelli G, Malagola M, Rondoni M, Visani G.

Leuk Lymphoma. 2004 Mar;45(3):637-8. No abstract available.

PMID:
15160933
41.

Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia.

Piccaluga PP, Luatti S, Ascani S, Bianchini M, Malagola M, Rondoni M, Gaitani S, Testoni N, Pileri SA, Baccarani M, Martinelli G, Visani G.

Cancer Genet Cytogenet. 2004 May;151(1):85-6. No abstract available.

PMID:
15120916
42.

Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia.

Piccaluga PP, Malagola M, Rondoni M, Amabile M, Paolini S, Soverini S, Gaitani S, Visani G, Baccarani M, Martinelli G.

Eur J Haematol. 2004 Apr;72(4):302-3. No abstract available.

PMID:
15089772
43.

Molecular monitoring to identify a threshold of CBFbeta/MYH11 transcript below which continuous complete remission of acute myeloid leukemia inv16 is likely.

Martinelli G, Rondoni M, Buonamici S, Ottaviani E, Piccaluga PP, Malagola M, Baccarani M.

Haematologica. 2004 Apr;89(4):495-7.

44.

Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly.

Piccaluga PP, Martinelli G, Rondoni M, Malagola M, Ronconi S, Visani G, Baccarani M.

Haematologica. 2003 Dec;88(12):ECR37. No abstract available.

45.

Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts.

Martinelli G, Ottaviani E, Buonamici S, Isidori A, Borsaru G, Visani G, Piccaluga PP, Malagola M, Testoni N, Rondoni M, Nucifora G, Tura S, Baccarani M.

Haematologica. 2003 Nov;88(11):1221-8.

46.

Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC.

Bianchini M, Ottaviani E, Grafone T, Giannini B, Soverini S, Terragna C, Amabile M, Piccaluga PP, Malagola M, Rondoni M, Bosi C, Baccarani M, Martinelli G.

Clin Chem. 2003 Oct;49(10):1642-50.

47.

Complete remission in acute myeloid leukemia with granulocyte-colony stimulating factor without chemotherapy. Report of cytogenetic remission of a t(9;11)(p22q23) positive AML patient and review of literature.

Piccaluga PP, Martinelli G, Malagola M, Rondoni M, Bianchini M, Visani G, Baccarani M.

Haematologica. 2003 Aug;88(8):ECR28. Review. No abstract available.

48.

Liposomal daunorubicin (DaunoXome) for treatment of relapsed meningeal acute myeloid leukemia.

Piccaluga PP, Visani G, Martinelli G, Isidori A, Malagola M, Rondoni M, Baccarani M, Tura S.

Leukemia. 2002 Sep;16(9):1880-1. No abstract available.

49.

Evaluation of mezlocillin in treatment of acute and chronic prostatitis.

Battista R, Corsetti G, Rondoni M, Lucchetti R.

J Chemother. 1989 Jul;1(4 Suppl):871-2. No abstract available.

PMID:
16312679
50.

Mitomycin C in the treatment of superficial bladder neoplasm.

Liberti M, De Berardinis E, Perugia G, Gentile V, Rondoni M, Riga T.

Panminerva Med. 1988 Jan-Mar;30(1):52-3. No abstract available.

PMID:
3138624

Supplemental Content

Loading ...
Support Center